# GLOW peptide Dosage Context: Constituent Research Figures Only > GLOW peptide has no validated blend dose. The constituent research figures for GHK-Cu, BPC-157 and TB-500 — concentrations, routes, and half-lives — read as context, never as a recommendation. No blend dose has ever been validated in a controlled human trial. These are constituent-level research figures, logged as context and nothing more. ## There is no validated GLOW peptide dose The first and most important fact about GLOW peptide dosing is the absence of one. The blend has never been dosed in a controlled human trial, so there is no validated or standardized dose for the GHK-Cu + BPC-157 + TB-500 combination. Everything below is constituent-level research data or a non-validated community and clinic convention, presented for context only. No figure on this page is a recommendation. Each is reported as 'studied at X in [species or model]' so the research framing stays intact. ## Constituent research figures, by leg GHK-Cu: in-vitro fibroblast collagen synthesis was driven at 10^-12 to 10^-9 M; topical cosmetic formulations run approximately 0.05% to 2% (w/w) [1][2]. BPC-157: rodent tissue-repair studies used roughly 10 ng to 10 microg per rat per day, intraperitoneally; the Achilles study tested 10 microg, 10 ng or 10 pg per kg once daily [3]. A first-in-human IV safety pilot used 10 mg then 20 mg in two adults [10]. TB-500 / thymosin beta-4: rodent wound and stroke studies inform the leg; the human Phase 1 study gave full-length thymosin beta-4 IV at 42, 140, 420 and 1260 mg [5]. The commonly cited research-label blend ratio of 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial is a supplier labeling convention, not a clinically validated dose. ## Half-life and routes studied No pharmacokinetic data exist for the GLOW blend as a unit; combination kinetics have never been characterized. Among the constituents, BPC-157 has a short elimination half-life — under 30 minutes in rats and dogs — with linear kinetics and rapid breakdown to amino acids. The free GHK tripeptide is cleared rapidly by plasma peptidases, while topical GHK-Cu forms a dermal copper depot. Thymosin beta-4 showed dose-proportional kinetics, with half-life increasing with dose in its human Phase 1 study. Routes studied are constituent-specific. GHK-Cu is predominantly topical, with rodent intraperitoneal and intranasal systemic studies [1]. BPC-157 was studied intraperitoneally and intramuscularly in animals and intravenously in the 2-subject human pilot [3][10]. Thymosin beta-4 was studied topically and intraperitoneally in animals and intravenously in humans [5]. Community 'GLOW' protocols describe subcutaneous injection of the reconstituted blend, but no peer-reviewed pharmacology supports subcutaneous blend dosing. ## Reconstitution and stability, in research handling Blend stability is formulation-specific and not characterized in the literature. In research handling, lyophilized BPC-157 and TB-500 are reconstituted with bacteriostatic water — sterile water containing 0.9% benzyl alcohol — and refrigerated. The GHK-Cu complex is most stable near pH 5-6.5, and its blue-violet color indicates an intact Cu(II) complex; strong reducing agents and low-pH actives such as ascorbic acid can break it. Co-formulating a copper complex with two other peptides raises theoretical compatibility questions — copper redox chemistry, pH — that have not been studied for GLOW specifically. None of this is an instruction; it is the handling context the literature describes. --- Three constituent channels read on one console — GHK-Cu, BPC-157 and TB-500 logged to their studies and their 503A status, with every blend-level gap printed in plain sight, nothing dispensed and nothing for sale.